(Q38881161)

7 September 2017

title

Blockade of CXCR6 reduces invasive potential of gastric cancer cells through inhibition of AKT signaling (English)

1 reference

7 September 2017

Ya Li

1 reference

7 September 2017

Li-Xia Fu

1 reference

7 September 2017

Wan-Lin Zhu

1 reference

7 September 2017

Hua Shi

1 reference

7 September 2017

Li-Jian Chen

1 reference

7 September 2017

Bin Ye

1 reference

7 September 2017

publication date

28 April 2015

1 reference

International Journal of Immunopathology and Pharmacology

7 September 2017

published in

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

194-200

1 reference

7 September 2017

cites work

Gastric cancer review

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Gastric cancer-molecular and clinical dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Clinical significance of hmgb1 expression in human gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

The expression and role of CXC chemokines in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

The CXCL16-CXCR6 chemokine axis in glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

CXCR6: the role of environment in tumor progression. Challenges for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

CXCL16 and CXCR6 in Ewing sarcoma family tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Role and clinicopathologic significance of CXC chemokine ligand 16 and chemokine (C-X-C motif) receptor 6 expression in gastric carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0394632015584502

21 January 2018

Identifiers

DOI

10.1177/0394632015584502

1 reference

7 September 2017

1 reference